Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
COGT Cogent Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: COGT
Price (delayed)
$4.81
Market cap
$547.65M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.84
Enterprise value
$438.74M
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed
Highlights
The company's debt fell by 8% YoY and by 2.2% QoQ
The EPS rose by 5% QoQ
Cogent Biosciences's quick ratio has plunged by 58% YoY and by 3.3% from the previous quarter
The company's equity fell by 48% YoY and by 15% QoQ
Key stats
What are the main financial stats of COGT
Market
Valuations
Earnings
Shares outstanding
113.86M
Market cap
$547.65M
Enterprise value
$438.74M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.5
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$288.47M
Net income
-$269.5M
EBIT
-$269.5M
EBITDA
-$265.07M
Free cash flow
-$222.82M
Per share
Balance sheet
Liquidity
EPS
-$1.84
EPS diluted
-$1.84
Free cash flow per share
-$1.97
Book value per share
$1.92
Revenue per share
$0
TBVPS
$2.5
Total assets
$283.8M
Total liabilities
$64.8M
Debt
$17.09M
Equity
$219M
Working capital
$203.57M
Debt to equity
0.08
Current ratio
5.13
Quick ratio
4.98
Net debt/EBITDA
0.41
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-75.6%
Return on equity
-92.7%
Return on invested capital
-121.3%
Return on capital employed
-114.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COGT stock price
How has the Cogent Biosciences stock price performed over time
Intraday
-3.41%
1 week
-18.06%
1 month
7.85%
1 year
-39.27%
YTD
-38.33%
QTD
-19.7%
Financial performance
How have Cogent Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$288.47M
Net income
-$269.5M
Gross margin
N/A
Net margin
N/A
COGT's operating income is down by 27% year-on-year and by 4.5% since the previous quarter
The company's net income fell by 27% YoY and by 5% QoQ
Price vs fundamentals
How does COGT's price correlate with its fundamentals
Growth
What is Cogent Biosciences's growth rate over time
Valuation
What is Cogent Biosciences stock price valuation
P/E
N/A
P/B
2.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 5% QoQ
The company's equity fell by 48% YoY and by 15% QoQ
The P/B is 19% below the last 4 quarters average of 3.1 but 14% above the 5-year quarterly average of 2.2
Efficiency
How efficient is Cogent Biosciences business performance
The company's return on equity fell by 46% YoY and by 24% QoQ
The ROA has contracted by 37% YoY and by 19% from the previous quarter
COGT's return on invested capital is down by 30% year-on-year and by 19% since the previous quarter
Dividends
What is COGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COGT.
Financial health
How did Cogent Biosciences financials performed over time
Cogent Biosciences's quick ratio has plunged by 58% YoY and by 3.3% from the previous quarter
COGT's current ratio has dropped by 57% year-on-year and by 3.6% since the previous quarter
The company's debt is 92% lower than its equity
Cogent Biosciences's debt to equity has surged by 100% YoY and by 14% QoQ
The company's equity fell by 48% YoY and by 15% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.